These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16941132)

  • 1. The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.
    Mizuno T; Katsumata N; Mukai H; Shimizu C; Ando M; Watanabe T
    Support Care Cancer; 2007 Mar; 15(3):287-91. PubMed ID: 16941132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer.
    Aquino VM; Herrera L; Sandler ES; Buchanan GR
    Cancer; 2000 Apr; 88(7):1710-4. PubMed ID: 10738231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
    Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).
    Clemons M; Mazzarello S; Hilton J; Joy A; Price-Hiller J; Zhu X; Verma S; Kehoe A; Ibrahim MF; Sienkiewicz M; Stober C; Vandermeer L; Hutton B; Mallick R; Fergusson D
    Support Care Cancer; 2019 Apr; 27(4):1345-1354. PubMed ID: 30099602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients.
    Escalante CP; Weiser MA; Manzullo E; Benjamin R; Rivera E; Lam T; Ho V; Valdres R; Lee EL; Badrina N; Fernandez S; DeJesus Y; Rolston K
    Support Care Cancer; 2004 Sep; 12(9):657-62. PubMed ID: 15185134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
    Mullen CA; Petropoulos D; Roberts WM; Rytting M; Zipf T; Chan KW; Culbert SJ; Danielson M; Jeha SS; Kuttesch JF; Rolston KV
    Cancer; 1999 Jul; 86(1):126-34. PubMed ID: 10391572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor.
    Papadimitris C; Dimopoulos MA; Kostis E; Papadimitriou C; Anagnostopoulos A; Alexopoulos G; Papamichael C; Gika D; Mitsibounas D; Stamatelopoulos S
    Oncology; 1999; 57(2):127-30. PubMed ID: 10461059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
    Vogel CL; Wojtukiewicz MZ; Carroll RR; Tjulandin SA; Barajas-Figueroa LJ; Wiens BL; Neumann TA; Schwartzberg LS
    J Clin Oncol; 2005 Feb; 23(6):1178-84. PubMed ID: 15718314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
    Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
    Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy.
    Takahashi M; Takahashi K; Ogawa K; Takashima T; Asano Y; Kashiwagi S; Noda S; Onoda N; Ohira M; Nagayama K
    Support Care Cancer; 2019 Aug; 27(8):2829-2836. PubMed ID: 30547304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.